Advertisement
Research Report
The fraction of strongly bound cross-bridges is increased in mice that carry the myopathy-linked myosin heavy chain mutation MYH4L342Q
Johan Lindqvist, Hiroyuki Iwamoto, Gonzalo Blanco, Julien Ochala
Disease Models & Mechanisms 2013 6: 834-840; doi: 10.1242/dmm.011155

SUMMARY

Myosinopathies have emerged as a new group of diseases and are caused by mutations in genes encoding myosin heavy chain (MyHC) isoforms. One major hallmark of these diseases is skeletal muscle weakness or paralysis, but the underlying molecular mechanisms remain unclear. Here, we have undertaken a detailed functional study of muscle fibers from Myh4arl mice, which carry a mutation that provokes an L342Q change within the catalytic domain of the type IIb skeletal muscle myosin protein MYH4. Because homozygous animals develop rapid muscle-structure disruption and lower-limb paralysis, they must be killed by postnatal day 13, so all experiments were performed using skeletal muscles from adult heterozygous animals (Myh4arl/+). Myh4arl/+ mice contain MYH4L342Q expressed at 7% of the levels of the wild-type (WT) protein, and are overtly and histologically normal. However, mechanical and X-ray diffraction pattern analyses of single membrane-permeabilized fibers revealed, upon maximal Ca2+ activation, higher stiffness as well as altered meridional and equatorial reflections in Myh4arl/+ mice when compared with age-matched WT animals. Under rigor conditions, by contrast, no difference was observed between Myh4arl/+ and WT mice. Altogether, these findings prove that, in adult MYH4L342Q heterozygous mice, the transition from weak to strong myosin cross-bridge binding is facilitated, increasing the number of strongly attached myosin heads, thus enhancing force production. These changes are predictably exacerbated in the type IIb fibers of homozygous mice, in which the embryonic myosin isoform is fully replaced by MYH4L342Q, leading to a hypercontraction, muscle-structure disruption and lower-limb paralysis. Overall, these findings provide important insights into the molecular pathogenesis of skeletal myosinopathies.

INTRODUCTION

Myosinopathies are a group of heterogeneous myopathies with wide clinical variability, including different grades of severity and ages of onset (congenital, childhood or adulthood) (Oldfors, 2007). They are often associated with skeletal muscle weakness or paralysis and are caused by mutations in genes encoding myosin heavy chain (MyHC) isoforms that are present in mammalian muscle in the fetus, newborn and/or adult [e.g. MYH3, MYH8, MYH7, MYH2 and MYH4 (encoding embryonic, perinatal, type I, type IIa and type IIb MyHC isoforms, respectively)] (Kurapati et al., 2012; Oldfors, 2007). To date, only a few of these mutations have been functionally characterized, preventing an in-depth molecular understanding of the weakness or paralysis in myosinopathies (Belus et al., 2008; Debold et al., 2007; Keller et al., 2004; Palmiter et al., 2000; Seebohm et al., 2009; Wang et al., 2003).

Mutations in genes encoding MyHCs are typically missense, resulting in the substitution of just one amino acid, and have been identified within the catalytic domain, converter and rod (backbone) regions of the myosin molecule (Rayment et al., 1995). The ones in the catalytic domain are of particular interest because this region is essential for actomyosin interaction, force production and motion. Indeed, it has (i) specific binding sites where phosphate (Pi), ATP and adenosine diphosphate (ADP) can be exchanged; and (ii) various actin-binding locations (Rayment et al., 1993a; Rayment et al., 1993b; Rayment et al., 1996). Recently, a mouse model expressing a particular MYH4 mutation, MYH4L342Q, in the catalytic domain of type IIb MyHC (MyHC IIb) was characterized (Kurapati et al., 2012). Homozygous mice (Myh4arl/Myh4arl) are indistinguishable from wild-type (WT) animals from birth to postnatal day 11. Nevertheless, from day 11, coinciding with the timing of replacement of neonatal and embryonic MyHC isoforms by the adult types, a sudden skeletal muscle degeneration process occurs as attested by the absence of structured thick filaments and accumulation of intracellular protein aggregates, leading to hind-limb paralysis by day 13 (Kurapati et al., 2012). The speed and severity of the myopathic phenotype in homozygous mice makes it difficult to use them to obtain insights into the molecular functional consequences of the MYH4L342Q myosin mutation. Heterozygous mice (Myh4arl/+) are, by contrast, a convenient source of material because they do not suffer from any overt pathological or morphological change in the muscles (Fig. 1) and have a normal lifespan. Crucially, quantitative proteomic analysis of the MyHC IIb content in the muscles of heterozygous mice has shown that MYH4L342Q is present at 7% of the WT protein levels (Kurapati et al., 2012). Interestingly, single membrane-permeabilized muscle fibers isolated from adult Myh4arl/+ animals have been shown to produce higher steady-state isometric maximal forces than those from WT (Fig. 1) (Kurapati et al., 2012). Thus, one can hypothesize that, in the presence of MYH4L342Q, the formation of strongly bound myosin cross-bridges is increased and this might be the molecular determinant of muscle-structure disruption and paralysis in Myh4arl/Myh4arl mice. In the present study, we aimed to test this by recording and analyzing the mechanics and X-ray diffraction patterns of muscle fibers from adult Myh4arl/+ and control mice.

Fig. 1.
Fig. 1.

Preserved muscle ultrastructure and increased force production in Myh4arl/+ mice. This figure depicts typical electron microscopy pictures for WT (A) and for Myh4arl/+ (B) mice, as well as the maximal steady-state isometric force production of membrane-permeabilized single fibers (C) for WT (black bar) and Myh4arl/+ (white bar). Asterisks denote significant differences (P<0.05) when compared with WT.

TRANSLATIONAL IMPACT

Clinical issue

Myosinopathies, which are caused by mutations in genes encoding myosin heavy chain (MyHC) isoforms, are an emerging group of inherited diseases that are characterized by skeletal muscle weakness, paralysis and degeneration. These diseases show wide clinical variability and, to date, the underlying mechanisms of paralysis are poorly understood. Recently, a mouse mutant expressing a particular mutation (Myh4arl) affecting myosin function was characterized. However, mice that are homozygous for this mutation are difficult to use to gain mechanistic insights into myosinopathies because of the speed and severity of muscular degeneration.

Results

In this work, the authors performed an in-depth functional study of muscle fibers in a unique mouse model that exhibits lower-limb paralysis and closely mimics human myosinopathies. To overcome problems encountered when working with Myh4arl homozygous mice, the authors studied heterozygous mice. By comparing the mechanics and X-ray diffraction patterns of mutated and wild-type muscle fibers, the authors provide evidence that the myosin mutation enhances the amount of strongly bound myosin cross-bridges and facilitates force production at the molecular and cellular level. These findings suggest a mechanism for the occurrence of hypercontraction, muscle-structure disruption and lower-limb paralysis in affected mice.

Implications and future directions

This study unveils for the first time the cascade of events leading to contractile deregulation in the presence of a myosin mutation. Thus, the work provides important insights into the molecular and cellular pathogenesis of myosinopathies. In light of these findings, future potential therapies should focus on restoring myosin function to reverse muscle paralysis.

RESULTS

Single membrane-permeabilized fiber mechanics

The MyHC isoform distribution was not different between Myh4arl/+ and WT mice (Fig. 2). Nevertheless, here, comparisons were restricted to cells expressing MyHC IIb. As previously shown (Kurapati et al., 2012), steady-state isometric force at saturating Ca2+ concentration ([Ca2+]) [−log10 [Ca2+] (pCa) 4.50] was significantly higher in Myh4arl/+ when compared with WT mice (Fig. 1). To analyze the behavior at non-saturating [Ca2+] (pCa 6.30-4.90), the relative force-pCa relationship was constructed (Fig. 2) and fitted using the following sigmoid Hill equation: F=[Ca2+]nH/([Ca50]nH + [Ca2+]nH), where F is force; −log10 [Ca50] is the midpoint (pCa50 or Ca2+ sensitivity); and nH is the Hill coefficient. pCa50 was significantly higher in Myh4arl/+ when compared with WT mice (Fig. 2). To obtain some information regarding the mechanisms underlying the force enhancement with MYH4L342Q, stiffness measurements were performed. Thus, step changes in fiber length were imposed (releases of 0.15, 0.3 and 0.5% of fiber length and stretches of the same amplitudes). Stiffness was defined as the slope of the linear regression of the relationship between the peak force response and the length change (Fig. 3). Active stiffness was significantly higher at saturating [Ca2+] (pCa 4.50) in Myh4arl/+ when compared with WT mice (Table 1). By contrast, under rigor conditions, where all myosin heads are attached owing to a very slow dissociation rate (Cooke and Franks, 1980), rigor stiffness was not different between Myh4arl/+ and WT mice (Table 1).

Fig. 2.
Fig. 2.

Increased fiber Ca2+ sensitivity of force in Myh4arl/+ mice. This figure displays the MyHC isoform distribution in EDL for WT (black) and Myh4arl/+ (white) (A) fibers, as well as the relative force-pCa relationships (B), Ca2+ sensitivity of force (pCa50) (C) and Hill coefficient (nH) (D). Values are shown as means and standard errors. Asterisks denote significant differences (P<0.05) when compared with WT.

Fig. 3.
Fig. 3.

Enhanced fiber stiffness in Myh4arl/+ mice. This figure shows typical peak force-length change relationships for WT (black circles) and Myh4arl/+ (white circles).

View this table:
Table 1.

Single muscle fiber mechanics

X-ray diffraction patterns

To gain further insights into the changes with the MYH4L342Q mutation, low-angle X-rays were recorded (Fig. 4) and the intensity changes of one myosin meridional reflection (1st MM) and two actin-layer lines (6th and 7th ALLs) were monitored and analyzed (Fig. 5). All these parameters were enhanced on addition of Ca2+ in WT as well as in Myh4arl/+ mice. Of particular interest, during activation, the 1st MM was significantly greater in Myh4arl/+ when compared with WT mice (Fig. 5). The 6th and 7th ALLs, by contrast, were not affected by the presence of the mutation (Fig. 5).

Fig. 4.
Fig. 4.

Typical low-angle X-ray diffraction reflection patterns. This figure shows diffraction patterns for WT (A,B) or Myh4arl/+ (C,D) mice in resting state (A,C) or upon activation (B,D).

Fig. 5.
Fig. 5.

Changes in low-angle X-ray diffraction reflections in Myh4arl/+ mice. Meridional (A), actin-layer lines (ALLs; B,C) and equatorial (D–F) reflections are presented. Values are shown as means and standard errors for WT (n=23; black circles) and Myh4arl/+ (n=21; white circles) mice. Asterisks denote significant differences (P<0.05) when compared with WT.

As for equatorial reflections (Fig. 6), the I1,1/I1,0 intensity ratios were calculated and gave information on the mass distribution between the thick and thin filaments. Under resting conditions, the I1,1/I1,0 intensity ratio was not different between Myh4arl/+ and WT mice (Fig. 5). Upon activation, this ratio was significantly greater in Myh4arl/+ when compared with WT mice (Fig. 5). The 1,0 equatorial reflections were also converted to d1,0 lattice spacings, using Bragg’s Law (Colson et al., 2007). This value is known to reflect the radial compressional forces. Under resting conditions and during contraction, d1,0 lattice spacings were not different between Myh4arl/+ and WT mice (Fig. 5). The widths of the 1,0 equatorial reflections (estimated via Δ1,0) were also similar between Myh4arl/+ and WT mice under resting conditions (Fig. 5), but were significantly greater, upon activation, in Myh4arl/+ when compared with WT mice (Fig. 5).

Fig. 6.
Fig. 6.

Typical equatorial reflection for WT mice.

DISCUSSION

Understanding the molecular functional effects of mutants in myosinopathies is crucial to establish potential therapeutic strategies. In the present study, we proved that, in the presence of MYH4L342Q, the strong binding of myosin heads to actin filaments is greatly modified during contraction, triggering an increase in force production and, ultimately, probably disrupting muscle structure when the number of mutated molecules is high.

Altered myosin binding to actin filaments

As shown in Fig. 1, the steady-state isometric maximal force of single membrane-permeabilized muscle fibers from heterozygous mice (Myh4arl/+) was greater when compared with WT cells. This can be due to either a higher number of strongly attached myosin cross-bridges and/or to a larger force per individual actomyosin interaction. To distinguish between these two alternatives, stiffness measurements were achieved. Active stiffness was higher in Myh4arl/+ when compared with WT fibers, whereas rigor stiffness was unchanged. This implies that the higher force in the presence of the mutation is mainly caused by an increase in the proportion of myosin heads that are strongly bound to actin filaments rather than a change in the force developed by individual cross-bridges. What are the underlying mechanisms? The fraction of strongly bound myosin cross-bridges depends on fapp/(fapp + gapp) (Brenner and Eisenberg, 1986; Huxley, 1957), with fapp being the rate constant for attachment and gapp the rate constant for detachment (Brenner, 1988). We can therefore hypothesize that, in the presence of the MYH4L342Q defect, either an increase in fapp and/or a decrease in gapp occurs. Because the rate of force redevelopment, ktr, was unchanged in Myh4arl/+ animals when compared with WT mice (Kurapati et al., 2012) and because ktr is proportional to fapp + gapp (Brenner and Eisenberg, 1986; Huxley, 1957), we suggest a direct effect on both fapp and gapp (faster fapp and slower gapp). Thus, one can postulate that the cross-bridge cycling kinetics is modified in Myh4arl/+ mice, inducing an increased time spent by individual myosin heads in a strongly bound force-generating state, and thus conducting to an increased proportion of strongly bound myosin cross-bridges.

X-ray data seemed to confirm the above findings. In the present study, the 1st MM and 6th and 7th ALLs were analyzed. The 1st MM (meridional reflection at 14.5 nm) is thought to reflect the average orientation of the myosin cross-bridges with respect to the thick-filament backbone (Huxley et al., 1983; Reconditi et al., 2005). Indeed, its intensity is weak when myosin heads are at oblique angles or have a wide range of axial angles. It becomes stronger when myosin cross-bridges are more perpendicular to the thick-filament axis, as is the case during contraction (Huxley et al., 1983; Reconditi et al., 2005). The 6th and 7th ALLs (actin-layer lines at 5.9 and 5.1 nm, respectively) are likely to provide information about actin monomers modifying their molecular shape (Yagi and Matsubara, 1988). In the present study, because the 6th and 7th ALLs were not different between WT and Myh4arl/+ mice, one can propose that the mutation does not affect actin conformational changes. By contrast, because the 1st MM was enhanced in the presence of MYH4L342Q, we suggest that the mean orientation of the myosin heads that are strongly bound to actin monomers is more perpendicular than those that are weakly bound. One reasonable explanation for this phenomenon is that the greater fraction of strongly bound cross-bridges is caused by fine tunings of fapp and gapp changing transitions (i) from the weak to the strong force-producing binding state; and (ii) from the strong to the weak state. In the present study, unfortunately, direct quantifications of fapp and gapp have not been performed but could constitute the main objective of one future study.

What are the potential causes of fapp and gapp modifications? L342 is a highly conserved amino acid located in the catalytic domain of the myosin molecule and very close to sites involved in ATP and ADP exchanges (Rayment et al., 1993a; Rayment et al., 1993b; Rayment et al., 1996). Consequently, the replacement of a leucine by a glutamine at position 342 might directly prevent proper ATP binding and/or ADP dissociation. In addition to this, the mutation could have other consequences. Indeed, as presented in Fig. 2, the effect on force production is exacerbated at submaximal [Ca2+]. The exact underlying mechanisms remain unclear, but a recent simple analytical model predicts that changes in fapp and gapp are likely to affect the Ca2+ sensitivity of force production (Sich et al., 2010). Other unknown phenomena might also occur. Further experiments are required to specifically study this aspect.

The analysis of the equatorial reflections also validates the mechanical results (Fig. 5). Indeed, the I1,1/I1,0 intensity ratio was much more increased during contraction in Myh4arl/+ mice when compared with WT rodents, indicating a more pronounced net transfer of mass from the thick to thin filaments, thus a greater number of myosin cross-bridges bound to actin monomers. In addition, interestingly, the widths of the equatorial reflections were larger in Myh4arl/+ when compared with WT mice (Fig. 5), reflecting a higher degree of variance in lattice spacing inhomogeneity. One plausible explanation is that the myofilaments are displaced from their equilibrium positions in the presence of the MYH4L342Q mutation, leading to a greater disorder of the hexagonal myofilament lattice under activating conditions.

When all the above findings are taken together, it seems that, in the presence of MYH4L342Q, the amount of strongly bound myosin cross-bridges is increased by ∼20–25% (Table 1, Fig. 5). However, in Myh4arl/+ animals, the mutant peptide is present at only 7% of the WT protein levels (Kurapati et al., 2012). From where does the discrepancy arise? It remains unknown. Nevertheless, as previously reported with a mutation in myosin light chain (Kazmierczak et al., 2012), mutant proteins expressed at very low levels (below 10%) might function as poison peptides that also alter the function of the normal proteins, leading to an overall myosin dysfunction (>20%).

Comparison with other MyHC mutations

A few other mutations located in the catalytic domain have been functionally studied and findings were analogous. For instance, MYH7R403Q and MYH7R403W, which lie in the actin-binding interface, do not alter the force per individual actomyosin interaction (keeping the myosin tilting to ∼7 nm) but prolong the time spent by each myosin molecule in the strong binding conformation (Palmiter et al., 2000) and promoting force generation (Belus et al., 2008; Debold et al., 2007; Keller et al., 2004). Similarly, the MYH7R453C mutation, located close to the nucleotide-binding pocket (Oldfors, 2007; Rayment et al., 1995), seems to allow myosin molecules to spend a greater fraction of the cross-bridge cycle strongly bound to actin filament, increasing the duty ratio and enhancing force production (Debold et al., 2007; Wang et al., 2003). Another mutation, MYH7R719W, close to the catalytic domain but located in the converter region, has been shown to increase the stiffness of individual myosin heads, leading to an increased resistance to elastic distortion and enhanced force production (Seebohm et al., 2009).

Conclusion

Taken together, the present data suggest that, in the presence of the MYH4L342Q mutation, many important dysfunctional processes happen. Myosin binding to actin monomers is favored, increasing the amount of strongly bound myosin cross-bridges. At the cellular level, this increases the steady-state isometric force production and helps explain why higher levels of MYH4L342Q in homozygous mice triggers hind-limb muscle paralysis and myofibrillar disorganization. Overall, all this has to be considered when designing future drug therapies for myosinopathies.

MATERIALS AND METHODS

Animals

Two- to three-month-old WT mice as well as age-matched heterozygous transgenic animals expressing MYH4L342Q (Myh4arl/+) were included in the analyses. A complete description of the mice can be found elsewhere (Kurapati et al., 2012). Mice were killed by cervical dislocation and skeletal muscles [tibialis anterior and extensor digitorum longus (EDL)] were dissected. All procedures involving animal care and handling were performed according to institutional guidelines and were reviewed and approved by the Uppsala Local Ethical Committee on Animal Research.

Muscle preparation

Specimens were placed in relaxing solution at 4°C. Bundles of ∼50 fibers were dissected free and then tied with surgical silk to glass capillary tubes at slightly stretched lengths. They were then treated with skinning solution (relaxing solution containing glycerol; 50:50 v/v) for 24 hours at 4°C, after which they were transferred to −20°C.

In addition, the muscle bundles were treated with sucrose, a cryoprotectant, within 1–2 weeks for long-term storage (Frontera and Larsson, 1997). They were detached from the capillary tubes and snap frozen in liquid-nitrogen-chilled propane and stored at −160°C.

Membrane-permeabilized fiber mechanical recordings and analyses

On the day of experiment, bundles were de-sucrosed, transferred to a relaxing solution and single fibers dissected. A fiber 1–2 mm long was left between connectors leading to a force transducer (model 400A, Aurora Scientific) and a lever arm system (model 308B, Aurora Scientific) (Larsson and Moss, 1993; Moss, 1979). The two extremities of the fiber were tightly attached to the connectors as previously described (Moss, 1979). The apparatus was mounted on the stage of an inverted microscope (model IX70; Olympus). The sarcomere length was set to 2.50–2.60 μm (optimal mouse sarcomere length where the force production is the highest) and controlled during the experiment using a high-speed video analysis system (model 901A HVSL, Aurora Scientific). The diameter of the fiber between the connectors was measured through the microscope at a magnification of 320× with an image analysis system prior to the mechanical experiments. Fiber depth was measured by recording the vertical displacement of the microscope nosepiece while focusing on the top and bottom surfaces of the fiber. The focusing control of the microscope was used as a micrometer. Cross-sectional area (CSA) was calculated from the diameter and depth, assuming an elliptical circumference, and was corrected for the 20% swelling that is known to occur during skinning (Moss, 1979). Diameter and depth were measured at three different locations along the length of each fiber and the mean was considered as representative of cell dimensions. Mechanical experiments were performed at 15°C and included force measurements (normalized to CSA) after various length steps at numerous [Ca2+] (pCas between 6.30 and 4.50), as previously described (Ochala et al., 2011; Ochala et al., 2008; Ochala et al., 2007).

For the mechanical recordings, relaxing and activating solutions contained (in mM) 4 Mg-ATP, 1 free Mg2+, 20 imidazole, 7 EGTA, 14.5 creatine phosphate, and KCl to adjust the ionic strength to 180 mM and pH to 7.0. The pre-activating solution was identical to the relaxing solution except that the EGTA concentration was reduced to 0.5 mM. The concentrations of free Ca2+ were 10−9 M (relaxing and pre-activating solutions) and 10−6.30, 10−5.90, 10−5.50, 10−5.10, 10−4.90 and 10−4.50 M (activating solutions), expressed as pCas (i.e. −log10 [Ca2+]). The rigor solution was the same as the regular activating solution except that MgATP and creatine phosphate were absent.

After mechanical recordings, each skinned fiber was placed in urea buffer (120 g urea, 38 g thiourea, 70 ml H2O, 25 g mixed bed resin, 2.89 g dithiothreitol, 1.51 g Trizma base, 7.5 g SDS, 0.004% bromophenol blue) in a plastic microcentrifuge tube and stored at −160°C. MyHC isoform composition of fibers was then determined by 6% SDS-PAGE. The acrylamide concentration was 4% (wt/vol) in the stacking gel and 6% in the running gel, and the gel matrix included 30% glycerol. Sample loads were kept small (equivalent to ∼0.05 mm of fiber segment) to improve the resolution of the myosin heavy chain bands (types I, IIa, IIx and IIb). Electrophoresis was performed at 120 V for 24 hour with a Tris-glycine electrode buffer (pH 8.3) at 15°C (SE 600 vertical slab gel unit, Hoefer Scientific Instruments). The gels were silver-stained and subsequently scanned in a soft laser densitometer (Molecular Dynamics) with a high spatial resolution (50 μm pixel spacing) and 4096 optical density levels.

X-ray diffraction recordings and analyses

Two to three days prior to X-ray recordings, bundles were de-sucrosed, transferred to a relaxing solution and single fibers were dissected. Arrays of ∼30 fibers were set up (Iwamoto, 2009; Iwamoto et al., 2001; Iwamoto et al., 2002; Iwamoto et al., 2003; Ochala et al., 2011; Ochala et al., 2010). For each fiber, both ends were clamped to half-split gold meshes for electron microscopy (width, 3 mm), which had been glued to precision-machined ceramic chips (width, 3 mm) designed to fit to a specimen chamber. The arrays were then transferred to the skinning solution and stored at −20°C. 44 arrays were mounted.

On the day of X-ray recordings, arrays were placed in a plastic dish containing a pre-activating solution and washed thoroughly to remove the glycerol. They were then transferred to the specimen chamber, capable of manual length adjustment and force measurement (force transducer, AE801, Memscap, Bernin, France), filled with a pre-activating solution. Mean sarcomere length was measured and set to 2.50 μm. Subsequently, X-ray diffraction patterns were recorded at 15°C, first in the pre-activating solution and then in the activating solution (pCa 4.50) when maximal steady-state isometric force was reached. It should be mentioned that the activating solution was supplied to the chamber by a remote-controlled pump.

For each array, ∼10–20 diffraction patterns were recorded for each solution at the BL45XU beamline of SPring-8 and were analyzed as described previously (Iwamoto, 2009; Iwamoto et al., 2001; Iwamoto et al., 2002; Iwamoto et al., 2003). The wavelength was 0.09 nm and the specimen-to-detector distance was 2 m. As a detector, a cooled CCD camera (C4880, Hamamatsu Photonics; 1000×1018 pixels) was used in combination with an image intensifier (VP5445, Hamamatsu Photonics). To minimize radiation damages, the exposure time was kept low (2 seconds) and the specimen chamber was moved by 100 μm after each exposure. Moreover, we placed an aluminum plate (thickness, 0.35–0.5 mm) upstream of the specimen chamber. The beam flux was estimated to be between 2.7×1011 and 4.0×1011 photons/second after attenuation, and the beam size at the sample position was 0.2 mm (vertical) and 0.3 mm (horizontal). Following X-ray recordings, background scattering was subtracted, and reflection intensities (except for equatorial reflections) were determined as described elsewhere (Iwamoto, 2009; Iwamoto et al., 2001; Iwamoto et al., 2002; Iwamoto et al., 2003; Yagi, 2003). The intensities of equatorial reflections were determined separately. First, the background (the region outside the area of 1,0 and 1,1 reflections) was approximated by a single exponential decay function, and this was subtracted from the observed intensity profile. The resulting curve should contain the profiles of 1,0, 1,1 and 2,0 reflections of the hexagonal lattice of myofibrils, and the profile of the square lattice of Z-line components. In this curve, the 1,0 is usually the most prominent reflection, and this was first fitted by a Gaussian distribution function and was subtracted from the rest of the curve. After this, the 1,1 is the most prominent reflection, and this was again fitted by a Gaussian. The intensities of 1,0 and 1,1 were defined as the areas below the fitted Gaussian curves. The lattice spacing was calculated from the peak position of the Gaussian curve.

Statistical analyses

Data are presented as means ± s.e.m. Sigma Stat software (Jandel Scientific) was used to generate descriptive statistics. The unpaired Student’s t-test was applied, and in cases where the data did not meet the criteria of normality (Kolmogorov-Smirnov test, P<0.05), the non-parametric Mann-Whitney rank-sum test was performed. Otherwise, regressions were performed and relationships were considered significantly different from zero at P<0.05.

Acknowledgements

We are grateful to Prof. L. Larsson for making the mechanical experiments possible. We also thank Y. Hedström and A. M. Gustafson for excellent technical assistance. The X-ray experiments were performed under approval of the SPring-8 Proposal Review Committee (2011A1042).

Footnotes

  • COMPETING INTERESTS

    The authors declare that they do not have any competing or financial interests.

  • AUTHOR CONTRIBUTIONS

    H.I., G.B. and J.O. conceived and designed the experiments. J.L., H.I., G.B. and J.O. performed the experiments. J.L., H.I. and J.O. analyzed the data. J.L., H.I., G.B. and J.O. wrote the paper.

  • FUNDING

    This study was supported by grants from STINT, from the Swedish Research Council and Harald och Greta Jeanssons Stiftelse to J.O., and from the UK Medical Research Council and the Biology Department, University of York, UK to G.B.

  • Received October 15, 2012.
  • Accepted January 10, 2013.

This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial Share Alike License (http://creativecommons.org/licenses/by-nc-sa/3.0), which permits unrestricted non-commercial use, distribution and reproduction in any medium provided that the original work is properly cited and all further distributions of the work or adaptation are subject to the same Creative Commons License terms.

REFERENCES

  1. ↵
    1. Belus, A.,
    2. Piroddi, N.,
    3. Scellini, B.,
    4. Tesi, C.,
    5. Amati, G. D.,
    6. Girolami, F.,
    7. Yacoub, M.,
    8. Cecchi, F.,
    9. Olivotto, I. and
    10. Poggesi, C.
    (2008). The familial hypertrophic cardiomyopathy-associated myosin mutation R403Q accelerates tension generation and relaxation of human cardiac myofibrils. J. Physiol. 586, 3639–3644.
    OpenUrlCrossRefPubMed
  2. ↵
    1. Brenner, B.
    (1988). Effect of Ca2+ on cross-bridge turnover kinetics in skinned single rabbit psoas fibers: implications for regulation of muscle contraction. Proc. Natl. Acad. Sci. USA 85, 3265–3269.
    OpenUrlAbstract/FREE Full Text
  3. ↵
    1. Brenner, B. and
    2. Eisenberg, E.
    (1986). Rate of force generation in muscle: correlation with actomyosin ATPase activity in solution. Proc. Natl. Acad. Sci. USA 83, 3542–3546.
    OpenUrlAbstract/FREE Full Text
  4. ↵
    1. Colson, B. A.,
    2. Bekyarova, T.,
    3. Fitzsimons, D. P.,
    4. Irving, T. C. and
    5. Moss, R. L.
    (2007). Radial displacement of myosin cross-bridges in mouse myocardium due to ablation of myosin binding protein-C. J. Mol. Biol. 367, 36–41.
    OpenUrlCrossRefPubMed
  5. ↵
    1. Cooke, R. and
    2. Franks, K.
    (1980). All myosin heads form bonds with actin in rigor rabbit skeletal muscle. Biochemistry 19, 2265–2269.
    OpenUrlCrossRefPubMedWeb of Science
  6. ↵
    1. Debold, E. P.,
    2. Schmitt, J. P.,
    3. Patlak, J. B.,
    4. Beck, S. E.,
    5. Moore, J. R.,
    6. Seidman, J. G.,
    7. Seidman, C. and
    8. Warshaw, D. M.
    (2007). Hypertrophic and dilated cardiomyopathy mutations differentially affect the molecular force generation of mouse alpha-cardiac myosin in the laser trap assay. Am. J. Physiol. 293, H284–H291.
    OpenUrl
  7. ↵
    1. Frontera, W. R. and
    2. Larsson, L.
    (1997). Contractile studies of single human skeletal muscle fibers: a comparison of different muscles, permeabilization procedures, and storage techniques. Muscle Nerve 20, 948–952.
    OpenUrlCrossRefPubMedWeb of Science
  8. ↵
    1. Huxley, A. F.
    (1957). Muscle structure and theories of contraction. Prog. Biophys. Biophys. Chem. 7, 255–318.
    OpenUrlPubMed
  9. ↵
    1. Huxley, H. E.,
    2. Simmons, R. M.,
    3. Faruqi, A. R.,
    4. Kress, M.,
    5. Bordas, J. and
    6. Koch, M. H.
    (1983). Changes in the X-ray reflections from contracting muscle during rapid mechanical transients and their structural implications. J. Mol. Biol. 169, 469–506.
    OpenUrlCrossRefPubMedWeb of Science
  10. ↵
    1. Iwamoto, H.
    (2009). Evidence for unique structural change of thin filaments upon calcium activation of insect flight muscle. J. Mol. Biol. 390, 99–111.
    OpenUrlCrossRefPubMedWeb of Science
  11. ↵
    1. Iwamoto, H.,
    2. Oiwa, K.,
    3. Suzuki, T. and
    4. Fujisawa, T.
    (2001). X-ray diffraction evidence for the lack of stereospecific protein interactions in highly activated actomyosin complex. J. Mol. Biol. 305, 863–874.
    OpenUrlCrossRefPubMedWeb of Science
  12. ↵
    1. Iwamoto, H.,
    2. Oiwa, K.,
    3. Suzuki, T. and
    4. Fujisawa, T.
    (2002). States of thin filament regulatory proteins as revealed by combined cross-linking/X-ray diffraction techniques. J. Mol. Biol. 317, 707–720.
    OpenUrlCrossRefPubMedWeb of Science
  13. ↵
    1. Iwamoto, H.,
    2. Wakayama, J.,
    3. Fujisawa, T. and
    4. Yagi, N.
    (2003). Static and dynamic x-ray diffraction recordings from living mammalian and amphibian skeletal muscles. Biophys. J. 85, 2492–2506.
    OpenUrlCrossRefPubMedWeb of Science
  14. ↵
    1. Kazmierczak, K.,
    2. Muthu, P.,
    3. Huang, W.,
    4. Jones, M.,
    5. Wang, Y. and
    6. Szczesna-Cordary, D.
    (2012). Myosin regulatory light chain mutation found in hypertrophic cardiomyopathy patients increases isometric force production in transgenic mice. Biochem. J. 442, 95–103.
    OpenUrlAbstract/FREE Full Text
  15. ↵
    1. Keller, D. I.,
    2. Coirault, C.,
    3. Rau, T.,
    4. Cheav, T.,
    5. Weyand, M.,
    6. Amann, K.,
    7. Lecarpentier, Y.,
    8. Richard, P.,
    9. Eschenhagen, T. and
    10. Carrier, L.
    (2004). Human homozygous R403W mutant cardiac myosin presents disproportionate enhancement of mechanical and enzymatic properties. J. Mol. Cell. Cardiol. 36, 355–362.
    OpenUrlCrossRefPubMedWeb of Science
  16. ↵
    1. Kurapati, R.,
    2. McKenna, C.,
    3. Lindqvist, J.,
    4. Williams, D.,
    5. Simon, M.,
    6. LeProust, E.,
    7. Baker, J.,
    8. Cheeseman, M.,
    9. Carroll, N.,
    10. Denny, P.,
    11. et al.
    (2012). Myofibrillar myopathy caused by a mutation in the motor domain of mouse MyHC IIb. Hum. Mol. Genet. 21, 1706–1724.
    OpenUrlAbstract/FREE Full Text
  17. ↵
    1. Larsson, L. and
    2. Moss, R. L.
    (1993). Maximum velocity of shortening in relation to myosin isoform composition in single fibres from human skeletal muscles. J. Physiol. 472, 595–614.
    OpenUrlCrossRefPubMedWeb of Science
  18. ↵
    1. Moss, R. L.
    (1979). Sarcomere length-tension relations of frog skinned muscle fibres during calcium activation at short lengths. J. Physiol. 292, 177–192.
    OpenUrlCrossRefPubMedWeb of Science
  19. ↵
    1. Ochala, J.,
    2. Li, M.,
    3. Tajsharghi, H.,
    4. Kimber, E.,
    5. Tulinius, M.,
    6. Oldfors, A. and
    7. Larsson, L.
    (2007). Effects of a R133W beta-tropomyosin mutation on regulation of muscle contraction in single human muscle fibres. J. Physiol. 581, 1283–1292.
    OpenUrlCrossRefPubMedWeb of Science
  20. ↵
    1. Ochala, J.,
    2. Li, M.,
    3. Ohlsson, M.,
    4. Oldfors, A. and
    5. Larsson, L.
    (2008). Defective regulation of contractile function in muscle fibres carrying an E41K beta-tropomyosin mutation. J. Physiol. 586, 2993–3004.
    OpenUrlCrossRefPubMed
  21. ↵
    1. Ochala, J.,
    2. Iwamoto, H.,
    3. Larsson, L. and
    4. Yagi, N.
    (2010). A myopathy-linked tropomyosin mutation severely alters thin filament conformational changes during activation. Proc. Natl. Acad. Sci. USA 107, 9807–9812.
    OpenUrlAbstract/FREE Full Text
  22. ↵
    1. Ochala, J.,
    2. Lehtokari, V. L.,
    3. Iwamoto, H.,
    4. Li, M.,
    5. Feng, H. Z.,
    6. Jin, J. P.,
    7. Yagi, N.,
    8. Wallgren-Pettersson, C.,
    9. Pénisson-Besnier, I. and
    10. Larsson, L.
    (2011). Disrupted myosin cross-bridge cycling kinetics triggers muscle weakness in nebulin-related myopathy. FASEB J. 25, 1903–1913.
    OpenUrlAbstract/FREE Full Text
  23. ↵
    1. Oldfors, A.
    (2007). Hereditary myosin myopathies. Neuromuscul. Disord. 17, 355–367.
    OpenUrlCrossRefPubMedWeb of Science
  24. ↵
    1. Palmiter, K. A.,
    2. Tyska, M. J.,
    3. Haeberle, J. R.,
    4. Alpert, N. R.,
    5. Fananapazir, L. and
    6. Warshaw, D. M.
    (2000). R403Q and L908V mutant beta-cardiac myosin from patients with familial hypertrophic cardiomyopathy exhibit enhanced mechanical performance at the single molecule level. J. Muscle Res. Cell Motil. 21, 609–620.
    OpenUrlCrossRefPubMedWeb of Science
  25. ↵
    1. Rayment, I.,
    2. Holden, H. M.,
    3. Whittaker, M.,
    4. Yohn, C. B.,
    5. Lorenz, M.,
    6. Holmes, K. C. and
    7. Milligan, R. A.
    (1993a). Structure of the actin-myosin complex and its implications for muscle contraction. Science 261, 58–65.
    OpenUrlAbstract/FREE Full Text
  26. ↵
    1. Rayment, I.,
    2. Rypniewski, W. R.,
    3. Schmidt-Bäse, K.,
    4. Smith, R.,
    5. Tomchick, D. R.,
    6. Benning, M. M.,
    7. Winkelmann, D. A.,
    8. Wesenberg, G. and
    9. Holden, H. M.
    (1993b). Three-dimensional structure of myosin subfragment-1: a molecular motor. Science 261, 50–58.
    OpenUrlAbstract/FREE Full Text
  27. ↵
    1. Rayment, I.,
    2. Holden, H. M.,
    3. Sellers, J. R.,
    4. Fananapazir, L. and
    5. Epstein, N. D.
    (1995). Structural interpretation of the mutations in the beta-cardiac myosin that have been implicated in familial hypertrophic cardiomyopathy. Proc. Natl. Acad. Sci. USA 92, 3864–3868.
    OpenUrlAbstract/FREE Full Text
  28. ↵
    1. Rayment, I.,
    2. Smith, C. and
    3. Yount, R. G.
    (1996). The active site of myosin. Annu. Rev. Physiol. 58, 671–702.
    OpenUrlCrossRefPubMedWeb of Science
  29. ↵
    1. Reconditi, M.,
    2. Linari, M.,
    3. Lucii, L.,
    4. Stewart, A.,
    5. Sun, Y. B.,
    6. Narayanan, T.,
    7. Irving, T.,
    8. Piazzesi, G.,
    9. Irving, M. and
    10. Lombardi, V.
    (2005). Structure-function relation of the myosin motor in striated muscle. Ann. N. Y. Acad. Sci. 1047, 232–247.
    OpenUrlCrossRefPubMedWeb of Science
  30. ↵
    1. Seebohm, B.,
    2. Matinmehr, F.,
    3. Köhler, J.,
    4. Francino, A.,
    5. Navarro-Lopéz, F.,
    6. Perrot, A.,
    7. Ozcelik, C.,
    8. McKenna, W. J.,
    9. Brenner, B. and
    10. Kraft, T.
    (2009). Cardiomyopathy mutations reveal variable region of myosin converter as major element of cross-bridge compliance. Biophys. J. 97, 806–824.
    OpenUrlCrossRefPubMedWeb of Science
  31. ↵
    1. Sich, N. M.,
    2. O’Donnell, T. J.,
    3. Coulter, S. A.,
    4. John, O. A.,
    5. Carter, M. S.,
    6. Cremo, C. R. and
    7. Baker, J. E.
    (2010). Effects of actin-myosin kinetics on the calcium sensitivity of regulated thin filaments. J. Biol. Chem. 285, 39150–39159.
    OpenUrlAbstract/FREE Full Text
  32. ↵
    1. Wang, Q.,
    2. Moncman, C. L. and
    3. Winkelmann, D. A.
    (2003). Mutations in the motor domain modulate myosin activity and myofibril organization. J. Cell Sci. 116, 4227–4238.
    OpenUrlAbstract/FREE Full Text
  33. ↵
    1. Yagi, N.
    (2003). An x-ray diffraction study on early structural changes in skeletal muscle contraction. Biophys. J. 84, 1093–1102.
    OpenUrlCrossRefPubMedWeb of Science
  34. ↵
    1. Yagi, N. and
    2. Matsubara, I.
    (1988). Changes in the 5.9 nm actin layer-line on activation of frog skeletal muscles. Adv. Exp. Med. Biol. 226, 369–380.
    OpenUrlPubMed
View Abstract
Back to top

RSSRSS

 Download PDF

Email
Research Report
The fraction of strongly bound cross-bridges is increased in mice that carry the myopathy-linked myosin heavy chain mutation MYH4L342Q
Johan Lindqvist, Hiroyuki Iwamoto, Gonzalo Blanco, Julien Ochala
Disease Models & Mechanisms 2013 6: 834-840; doi: 10.1242/dmm.011155
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
Citation Tools
Alerts

Article navigation

Other journals from The Company of Biologists

Advertisement

DMM and COVID-19

We are aware that the COVID-19 pandemic is having an unprecedented impact on researchers worldwide. The Editors of all The Company of Biologists’ journals have been considering ways in which we can alleviate concerns that members of our community may have around publishing activities during this time. Read about the actions we are taking at this time.

Please don’t hesitate to contact the Editorial Office if you have any questions or concerns.

Travel grants and how to use them (when there’s no travel)

“2020 may be a year of imaginary travel across Zoom backgrounds, but the science is still happening and we’re not planning on missing it.”

Read our Editorial, which explains how DMM and its publisher, The Company of Biologists, have adapted the financial support they provide in response to the ongoing pandemic.

Interviews – Shohei Yoshimoto, Patricia Shaw, Jelmer Hoeksma

First authors Shohei Yoshimoto, Patricia Shaw and Jelmer Hoeksma each take us behind the scenes of their latest papers in DMM, discussing the merits of their model systems, the implications of their work and life as an early-career researcher.

Fibrodysplasia ossificans progressiva: current concepts from bench to bedside

Arun-Kumar Kaliya-Perumal, Tom J. Carney and Philip W. Ingham present a comprehensive summary of the recent literature on this debilitating condition and discuss approaches to solving this clinical puzzle.

Call for papers - The RAS Pathway: Diseases, Therapeutics and Beyond

DMM invites you to submit original research for a special issue focused on targeting the RAS pathway. The submission deadline is 1 March 2021. Find out more and showcase your breakthrough research in this special collection. 

Pathological evaluation of rats carrying in-frame mutations in the dystrophin gene: a new model of Becker muscular dystrophy

In October’s Editor’s choice, Yamanouchi et al’s newly established rat model exhibits the dystrophic phenotype and abnormal dystrophin expression profile, similar to patients with Becker muscular dystrophy.